Sinotherapeutics Inc. (688247)

Overview

Sinotherapeutics Inc. is a specialty pharmaceutical company based in Shanghai, China, established in 2012. The company focuses on the development of generic and formulation products specifically tailored for the Chinese market. By offering a range of pharmaceutical products and comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) services, Sinotherapeutics Inc. aims to address the diverse needs of patients and healthcare professionals in China. The company's strategic approach to innovation and its commitment to quality have positioned it as a key player in the pharmaceutical industry in China.

Products and Services

Sinotherapeutics Inc. provides a diverse portfolio of pharmaceutical products and a suite of CRO/CDMO services, as detailed below:

• Posaconazole Delayed-Release Tablets: These are antifungal medications used to prevent and treat invasive fungal infections, particularly in immunocompromised patients.
• Ursodeoxycholic Acid Capsules: This medication is primarily used for the treatment of primary biliary cholangitis and to dissolve gallstones in patients who do not require gallbladder surgery.
• Bupropion Hydrochloride Extended-Release Tablets: An antidepressant that is also used to help with smoking cessation, reducing withdrawal effects.
• Paroxetine Extended-Release Tablets: This is an SSRI antidepressant used for treating major depressive disorder, anxiety disorders, and PTSD.
• Sevelamer Carbonate Tablets: These are used to control hyperphosphatemia (elevated phosphate levels in the blood) in patients with chronic kidney disease on dialysis.
• Propafenone Hydrochloride Extended-Release Capsules: A medication used in the treatment of certain types of serious (possibly fatal) irregular heartbeat (such as atrial fibrillation).

In addition to pharmaceutical products, Sinotherapeutics Inc. also offers extensive CRO/CDMO services to support the pharmaceutical industry. These services include:

• Pre-formulation Study: Critical early-stage development activities focusing on the physical and chemical properties of a drug substance, aiming to determine the appropriate form and formulation of a pharmaceutical product.
• Formulation and Process Development: The design of a stable and effective drug product along with the development of reliable manufacturing processes.
• Clinical Sample Manufacturing: Production of clinical trial materials that meet regulatory standards for human trials.
• NDA Registration Batch Manufacturing: The manufacturing of batches of a drug intended for New Drug Application (NDA) submission to regulatory bodies.
• Quality Standard Establishment: Development and implementation of quality standards and procedures to ensure the safety, efficacy, and quality of pharmaceutical products.
• Regulatory Dossier Document Preparation and Submission: Compilation and submission of the necessary documentation to regulatory authorities for the approval of pharmaceutical products and processes.